P-030 First Results from the RedirecTT-1 Study with Teclistamab (tec) + Talquetamab (tal) Simultaneously Targeting BCMA and GPRC5D in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM)
HemaSphere（2023）
Key words
MM,relapsed/refractory multiple myeloma,bispecifics,multiple myeloma,Phase I
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined